Lilly forced to halt two prasugrel studies

Eli Lilly and Co. announced Wednesday its suspension of two small trials of prasugrel, a blood-thinning drug it developed with Daiichi Sankyo Co., due to dosage concerns. The company said the studies will remain suspended until their procedures are modified, but affirmed its plan to seek FDA approval for the drug by the end of the year.

View Full Article in:

Wall Street Journal (tiered subscription model), The · CNNMoney

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC